Educational Notice
Peptidings provides information for educational and research purposes only. The compounds in this research cluster are subjects of ongoing scientific investigation at varying stages of development. None of the information presented here constitutes medical advice or a recommendation for use. Consult a qualified healthcare provider before making any decisions about peptide use.
Research Cluster
Sexual Health & Reproductive Peptides
This is the most evidence-dense cluster on Peptidings outside of weight loss. Five of the seven compounds here are FDA-approved drugs with defined clinical indications—not research-stage peptides extrapolated from preclinical data. That distinction matters enormously when evaluating community claims about sexual health peptide protocols.
It also introduces the most important caveat in this cluster: FDA approval for one indication does not authorize or validate use for another. GnRH agonists are approved to suppress testosterone in prostate cancer—not to enhance sexual function. Oxytocin is approved to induce labor—not as an intranasal arousal enhancer. The mechanism-to-application logic needs to be evaluated for each compound on its own terms.
Cluster at a Glance
7 compounds • 5 FDA-approved • 1 Phase II clinical program • 1 pilot/limited human data • Highest approval density on the site
Approved Drug
Clinical Trials
Pilot / Human Data
Editorial note: FDA approval for a specific indication does not validate off-label use for sexual health applications. Each compound’s approved indication and the sexual health application it is used for in community and self-experimentation contexts are documented separately. Where those uses are pharmacologically misaligned, that is stated plainly.
Leuprolide: What the Research Actually Shows
FDA-approved GnRH agonist that paradoxically suppresses sex hormones through continuous receptor desensitization. Standard of care for prostate cancer ADT, endometriosis, uterine fibroids, and central precocious puberty. Cross-cluster compound covering both Sexual Health and Oncology applications.
Read the research →
Melanotan II: What the Research Actually Shows
Melanotan II activates MC1R for tanning and MC3R/MC4R for libido — the same receptors as PT-141. The accidental discovery story, the receptor map, and the safety profile that matters.
Read the research →
PT-141 (Bremelanotide): What the Research Actually Shows
The only FDA-approved peptide specifically for sexual dysfunction — bremelanotide activates MC3R and MC4R in the hypothalamus to generate sexual desire centrally, bypassing the vascular mechanism entirely. Approved for HSDD in premenopausal women; off-label in men via compounding.
Read the research →
How These Compounds Relate
The seven compounds in this cluster operate at different levels of the reproductive and sexual hormone axis. Gonadorelin and kisspeptin act at the top of the cascade—kisspeptin regulates GnRH pulsatility upstream; gonadorelin is GnRH itself. Leuprolide and cetrorelix act at the pituitary level, modulating GnRH receptor signaling to suppress LH and FSH. PT-141 bypasses the hormonal axis entirely, acting on central melanocortin receptors to drive sexual desire. Oxytocin acts on bonding and arousal circuitry. Relaxin acts peripherally on genital tissue vasodilation and compliance.
The most important relationship in this cluster is the one between gonadorelin and leuprolide—and why they are not interchangeable despite both being GnRH-related. Gonadorelin administered in a pulsatile pattern stimulates LH and FSH, supporting testosterone production. Leuprolide administered continuously suppresses LH and FSH, driving testosterone to castrate levels. The distinction is not dosing—it is the pattern of administration and the direction of the resulting pharmacological effect. One supports sexual health in hormonally deficient men; the other actively suppresses it.
PT-141 is the only compound in this cluster approved specifically for a sexual health indication, and it is the evidence anchor for the sexual health conditions page. Its MC4R mechanism is distinct from everything else in this cluster—it does not act through the hormonal axis at all. This makes it relevant across a broader population than the GnRH-axis compounds, which are primarily relevant where hormonal dysregulation is the underlying cause.
Kisspeptin is the most scientifically interesting emerging compound in this cluster. Its role as the upstream GnRH gatekeeper gives it a uniquely central position in reproductive endocrinology, and the fMRI arousal data from the Imperial College group represents unusually direct evidence of a central sexual arousal effect. Whether that translates to a clinically meaningful sexual health application in a non-deficient population is an open question the current Phase II data is beginning to address.